MST1R — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL106738	0.64	19/20
SCHEMBL172005	0.62	19/20
SCHEMBL106695	0.69	18/20
SCHEMBL110308	0.63	16/20
SCHEMBL105538	0.54	16/20
SCHEMBL107201	0.51	16/20
SCHEMBL107202	0.51	16/20
SCHEMBL103903	0.62	15/20
SCHEMBL108496	0.74	14/20
SCHEMBL106696	0.81	13/20
SCHEMBL169838	0.71	13/20
SCHEMBL106579	0.53	13/20
SCHEMBL106324	0.49	13/20
Sitravatinib (SCHEMBL172015)	0.76	12/20
SCHEMBL105450	0.60	12/20
SCHEMBL305789	0.55	11/20
SCHEMBL171868	0.57	10/20
SCHEMBL306024	0.57	9/20
SCHEMBL104989	0.56	9/20
SCHEMBL171880	0.53	8/20

Clinical trials — most relevant to MST1R by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Ramipril in Suppressing ST2 Expression in Rheumatic Mitral Stenosis Patients	PHASE3	UNKNOWN
Denosumab and Male Infertility: a RCT	PHASE2	COMPLETED
NAPO - Novel Approach for Oligospermia	PHASE1/PHASE2	COMPLETED
FITMI - First In Treating Male Infertility	PHASE2	ACTIVE_NOT_RECRUITING
NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer	PHASE2	UNKNOWN
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy	PHASE2	COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer	PHASE1/PHASE2	UNKNOWN
Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma	PHASE2	ACTIVE_NOT_RECRUITING
Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia	PHASE2	COMPLETED
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer	PHASE1	COMPLETED
Presurgical Trial of Denosumab in Breast Cancer	EARLY_PHASE1	COMPLETED
A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET	nan	RECRUITING
Cancer Fusion Hybrids and Desmoplasia	nan	UNKNOWN
Beta-Hydroxy-Beta-Methylbutyrate Supplementation and Physical Activity in Liver Cirrhosis: a Controlled Trial	nan	UNKNOWN
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED
MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease	nan	COMPLETED
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)	nan	RECRUITING
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Serum TAM Receptor Tyrosine Kinase Ligands in Acute Pancreatitis	nan	COMPLETED
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Tumor Kinase Inhibitor Concentrations Measured by PET	nan	COMPLETED
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma	nan	SUSPENDED
Effect of Mechanical Ventilation on Plasma Concentration Level of R-spondin Proteins	nan	COMPLETED
Circular RNA and Chemerin in Breast Cancer Patient	nan	UNKNOWN
Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MST1R binder may also engage these)

Protein	Name	Similarity
Q62190	—	0.998	Q62190 →
Q3UH93	—	0.990	Q3UH93 →
Q8CJH3	—	0.989	Q8CJH3 →
Q5EA85	—	0.988	Q5EA85 →
A1X150	—	0.987	A1X150 →
INSRR	Insulin receptor-related protein	0.987	landscape →
Q92729	—	0.986	Q92729 →
Q9H3S1	—	0.986	Q9H3S1 →
Q9QZC2	—	0.985	Q9QZC2 →
Q62178	—	0.985	Q62178 →
P0C0K6	—	0.985	P0C0K6 →
O43157	—	0.984	O43157 →
Q9DBX3	—	0.984	Q9DBX3 →
Q8BYG9	—	0.984	Q8BYG9 →
P0C0K7	—	0.984	P0C0K7 →
Q9WTL4	—	0.983	Q9WTL4 →
Q9UGT4	—	0.983	Q9UGT4 →
Q7TN88	—	0.983	Q7TN88 →
Q8R0S6	—	0.983	Q8R0S6 →
Q96PQ0	—	0.982	Q96PQ0 →
Q6QNU9	—	0.982	Q6QNU9 →
O08852	—	0.982	O08852 →
P14617	—	0.982	P14617 →
Q7TQH7	—	0.982	Q7TQH7 →
O15031	—	0.982	O15031 →
Q2IBC0	—	0.982	Q2IBC0 →
Q2KHV9	—	0.982	Q2KHV9 →
Q00PJ8	—	0.981	Q00PJ8 →
PIGO	GPI ethanolamine phosphate transferase 3, catalytic subunit	0.981	landscape →
Q64716	—	0.981	Q64716 →